In order for our site to display correctly you will need a newer version of your web browser.
The following browsers support numerous web standards including CSS,XHTML, and the DOM (a universal means of controlling the behavior of web pages):
- Netscape v7 or higher (all platforms), Mozilla FireFox (Windows), Camino (Mac OS X), Galeon (Linux GNOME Desktop) or other browser stemming from the Mozilla.org project.
- Opera v7 or higher (Windows, Linux)
- Apple's Safari (Mac OS X)
- Konqueror (Linux KDE Desktop)
- Microsoft Internet Explorer v6 or higher (Windows) or v5 or higher (Macintosh)
Please note that this is not intended be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Finding Cures. Saving Children.
Leukemia / Lymphoma Protocols / Clinical Studies
For information on these and other studies, referring physicians may e-mail protocolinfo@stjude.org or call toll free physician referral line, 1-888-226-4343. If you are not a physician, please e-mail info@stjude.org for information on St. Jude studies.
A Study of Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia (ALLR17)
For: acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma
Phase I Study of Bevacizumab and Sorafenib Combined with Low Dose Cyclophosphamide in Patients with Refractory Solid Tumors and Leukemia
For: Recurrent or refractory solid tumors and leukemias
A Reduced Intensity Conditioning Regimen with CD3-Depleted Hematopietic Stem Cells to Improve Survival for Patients with Hematologic Malignancies Undergoing Haploidentical Stem Cell Transplantation
For: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), Juvenile Myelomonocytic Leukemia (JMML), Paroxysmal Nocturnal Hemoglobinuria (PNH), Hodgkin lymphoma, Non-Hodgkin Lymphoma, Myelodysplastic Syndrome (MDS)
Stanford V Chemotherapy with Low-Dose Tailored-Field Radiation Therapy for Intermediate Risk Pediatric Hodgkin's Disease
For: Hodgkin lymphoma
Reduced duration Stanford V Chemotherapy with low-dost tailored-field radiation therapy for favorable risk pediatric Hodgkin lymphoma
For: Hodgkin lymphoma
HLA - Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less than 2 Years of Age with Hematologic Malignancies
For: Leukemias (high risk hematologic malignancies)
Pilot Study of Haplo-Identical Natural Killer Cell Transplantation for Acute Myeloid Leukemia
For: Acute myeloid leukemia
Pilot Study of Expanded, Activated Haploidentical Natural Killer Cell Infusions for Non-B Lineage Hematologic Malignancies
For: Refractory or relapsed leukemia (AML, T-ALL, CML, JMML), T-cell lymphoma, and myelodysplastic syndrome
Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies (NKHEM)
For: Non-acute myeloid leukemia hematologic malignancies
Haploidentical hematopoietic stem cell transplantation using a novel Clofarabine containing conditioning regimen for patients with refractory hematologic malignancies
For: Acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), juvenile myelomonocytic leukemia (JMML), Hodgkin lymphoma, non-Hodgkin lymphoma, myelodysplastic syndrome (MDS)
A Pilot Pharmacokinetic, Pharmacodynamic, and Feasibility Study of Sorafenib in Combination with Cytarabine and Clofarabine in Patients with Refractory or Relapsed Hematologic Malignancies
For: Acute myeloid leukemia (AML), acute promyelocytic leukemia (APL), acute lymphoblastic leukemia (ALL), infantile leukemia (both AML and ALL), AML w/prior myelodysplastic syndrome (MDS), myelodysplastic / myeloproliferative neoplasms, biphenotypic leukemia
Total Therapy Study XVI for Newly Diagnosed Patients with Acute Lymphoblastic Leukemia
For: Acute Lymphoblastic Leukemia
Non St. Jude Protocols
A Phase I Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (Bay 43-9006, NSC#724772, IND#69896) in Children with Refractory Solid Tumors or Refractory Leukemias (ADVL0413)
For: All Leukemias, Solid Tumors
Killer Immunoglobulin-Like Receptor (KIR) Incompatible Hematopoietic Cell Transplantation (HCT) for Refractory and Relapsed Acute Myelogenous Leukemia (AML) in Children: A Children’s Oncology Group (COG) Study (AAML05P1)
For: Refractory and relapsed acute myelogenous leukemia (AML)
A Pilot Study of Lestaurtinib (CEP-701) in Combination with Chemotherapy in Young patients with Relapsed or Refractory FLT3-mutant Acute Myeloid Leukemia (AAML06P1)
For: Relapsed or refractory FLT3-mutant acute myeloid leukemia
A phase I, multi-center, dose escalation study of CAT-8015 in children, adolescents and young adults with refractory CD22+ acute lymphoblastic leukemia (ALL), or non-Hodgkin’s Lymphoma (NHL) (CAT-8015-1004)
For: acute lymphoblastic leukemia (ALL), non-Hodgkin’s lymphoma (NHL), including lymphoblastic lymphoma, Burkitt’s lymphoma, and large cell lymphoma
A Phase I/II Dose Escalation Study of Clofarabine in Combination with Etoposide and Cyclophosphamide in Pediatric Patients with Refractory or Relapsed Acute Leukemias
For: Refractory or relapsed acute leukemia
A Randomized Phase II Study of Bortezomib (PS-341), Velcade, IND 58443, NSC 681239) in Combination with Ifosfamide/Vinorelbine in Pediatric Patients with Relapsed/Refractory Hodgkin Disease
For: Hodgkin lymphoma
A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) with Standard APO (Doxorubicin, Prednisone, Vincristine) versus Consolidation with a Regimen Including Vinblastine
For: non-Hodgkin lymphoma, anaplastic large cell lymphoma
A Phase I Pharmacokinetic Optimal Dosing Study of Intraventricular Topotecan for Children with Neoplastic Meningitis
For: Neoplastic meningitis
